TTNP - Titan Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
3,113
5,911
215
15,065
1,671
Cost of Revenue
1,018
538
-
-
0
Gross Profit
2,095
5,373
-
-
1,671
Operating Expenses
Research Development
7,516
7,478
9,648
6,126
4,675
Selling General and Administrative
10,184
6,866
5,069
4,596
3,755
Total Operating Expenses
16,480
13,637
14,717
10,722
8,430
Operating Income or Loss
-14,385
-8,264
-14,502
4,343
-6,759
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-
128
564
755
-4,520
Income Before Tax
-15,263
-9,023
-14,307
5,135
-11,279
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-15,263
-9,023
-14,307
5,135
-11,279
Net Income
-15,263
-9,023
-14,307
5,135
-11,279
Net Income available to common shareholders
-15,548
-9,308
-14,307
5,135
-11,279
Reported EPS
Basic
-
-0.78
-4.02
1.50
-3.36
Diluted
-
-0.79
-4.20
1.20
-3.36
Weighted average shares outstanding
Basic
-
11,958
3,534
3,457
3,342
Diluted
-
11,958
3,538
3,577
3,342
EBITDA
-
-7,884
-14,085
4,720
-6,401